Q2 FY26: Standalone H1 PAT down 11%; bonus issue completed

Results restatedExceptional itemResults View source PDF Explain this filing

SHILPAMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹399.00

prior close

₹401.75

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%-2.4% vs market

Pharmaceuticals peers, median of 157sector-0.0%-2.5% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.8

10m

-1.4

15m

-0.9

30m

-2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.1-2.4-0.0-2.5

Next day

-5.3-0.2-5.1-0.4-4.8

-5.6+0.4-6.0-0.3-5.2

-9.0-0.4-8.6-1.0-8.0

-9.0-0.6-8.5-1.3-7.7

-10.7-0.9-9.8-1.5-9.2

-9.0-3.0-6.0-3.2-5.8

15d

-16.0-3.9-12.1-3.4-12.6

-19.0-4.8-14.2-4.0-15.0

-25.6-7.8-17.8-6.6-18.9

-18.3-7.2-11.0-8.5-9.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q2 and H1 FY26 results. Standalone Q2 revenue up 4% to Rs 135 cr but H1 PAT fell 11% to Rs 51.5 cr. Consolidated H1 revenue rose 9% to Rs 691 cr; PAT Rs 91 cr (boosted by tax reversal from merger). Completed 1:1 bonus Oct 7 and NCLT approved merger of INM Technologies unit. Plans 31% stake sale in JV Sravathi Advance Process for Rs 49.6 cr. Exceptional losses from subsidiary impairments and legal settlement. Unmodified audit opinion.

Likely market impact

Mixed performance: standalone H1 PAT fell 11% YoY. Bonus shares already allotted; key actions (merger, JV stake sale) closed this period.